145 related articles for article (PubMed ID: 11506491)
1. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.
Goldstein AM; Liu L; Shennan MG; Hogg D; Tucker MA; Struewing JP
Br J Cancer; 2001 Aug; 85(4):527-30. PubMed ID: 11506491
[TBL] [Abstract][Full Text] [Related]
2. Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families.
Hashemi J; Bendahl PO; Sandberg T; Platz A; Linder S; Stierner U; Olsson H; Ingvar C; Hansson J; Borg A
Genes Chromosomes Cancer; 2001 Jun; 31(2):107-16. PubMed ID: 11319798
[TBL] [Abstract][Full Text] [Related]
3. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.
Yakobson E; Eisenberg S; Isacson R; Halle D; Levy-Lahad E; Catane R; Safro M; Sobolev V; Huot T; Peters G; Ruiz A; Malvehy J; Puig S; Chompret A; Avril MF; Shafir R; Peretz H; Bressac-de Paillerets B
Eur J Hum Genet; 2003 Apr; 11(4):288-96. PubMed ID: 12700603
[TBL] [Abstract][Full Text] [Related]
4. The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy.
Gensini F; Sestini R; Piazzini M; Vignoli M; Chiarugi A; Brandani P; Ghiorzo P; Salvini C; Borgognoni L; Palli D; Bianchi-Scarrà G; Carli P; Genuardi M
Melanoma Res; 2007 Dec; 17(6):387-92. PubMed ID: 17992122
[TBL] [Abstract][Full Text] [Related]
5. New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment.
Kannengiesser C; Dalle S; Leccia MT; Avril MF; Bonadona V; Chompret A; Lasset C; Leroux D; Thomas L; Lesueur F; Lenoir G; Sarasin A; Bressac-de Paillerets B
Genes Chromosomes Cancer; 2007 Aug; 46(8):751-60. PubMed ID: 17492760
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of the CDKN2A promoter in Australian melanoma families.
Pollock PM; Stark MS; Palmer JM; Walters MK; Aitken JF; Martin NG; Hayward NK
Genes Chromosomes Cancer; 2001 Sep; 32(1):89-94. PubMed ID: 11477665
[TBL] [Abstract][Full Text] [Related]
7. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A mutations in multiple primary melanomas.
Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
[TBL] [Abstract][Full Text] [Related]
9. CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families.
Lang J; Boxer M; MacKie RM
Br J Dermatol; 2005 Dec; 153(6):1121-5. PubMed ID: 16307646
[TBL] [Abstract][Full Text] [Related]
10. Familial melanoma, pancreatic cancer and germline CDKN2A mutations.
Goldstein AM
Hum Mutat; 2004 Jun; 23(6):630. PubMed ID: 15146471
[TBL] [Abstract][Full Text] [Related]
11. Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases.
Levanat S; Situm M; Crnić I; Marasović D; Puizina-Ivić N; Pokupcić N; Musani V; Komar A; Kubat M; Furac I; Karija-Vlahović M; Krizanac S
Croat Med J; 2003 Aug; 44(4):418-24. PubMed ID: 12950144
[TBL] [Abstract][Full Text] [Related]
12. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
[TBL] [Abstract][Full Text] [Related]
13. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
[TBL] [Abstract][Full Text] [Related]
14. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
[TBL] [Abstract][Full Text] [Related]
15. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families.
Goldstein AM; Martinez M; Tucker MA; Demenais F
Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):889-94. PubMed ID: 11008905
[TBL] [Abstract][Full Text] [Related]
16. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.
Auroy S; Avril MF; Chompret A; Pham D; Goldstein AM; Bianchi-Scarrà G; Frebourg T; Joly P; Spatz A; Rubino C; Demenais F; Bressac-de Paillerets B;
Genes Chromosomes Cancer; 2001 Nov; 32(3):195-202. PubMed ID: 11579459
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
[TBL] [Abstract][Full Text] [Related]
18. The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry.
Lang J; Hayward N; Goldgar D; Tsao H; Hogg D; Palmer J; Stark M; Tobias ES; MacKie R
Genes Chromosomes Cancer; 2007 Mar; 46(3):277-87. PubMed ID: 17171691
[TBL] [Abstract][Full Text] [Related]
19. Role of the CDKN2A locus in patients with multiple primary melanomas.
Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M
J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862
[TBL] [Abstract][Full Text] [Related]
20. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations.
Goldstein AM; Landi MT; Tsang S; Fraser MC; Munroe DJ; Tucker MA
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2208-12. PubMed ID: 16172233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
